165807-01-2

Upstream product

• 7732-18-5 water 
• 165806-41-7 4-(4-Fluorophenyl)-1-[3-(4-morpholinyl)propyl]-5-(2-chloropyridin-4-yl)-imidazole 
• 165806-85-9 4'-fluorophenyl-(tolylthio)methylisocyanide 
• 165806-84-8 N-[(4-Fluoro-phenyl)-p-tolylsulfanyl-methyl]-formamide 
• 459-57-4 4-fluorobenzaldehyde 

Relevant academic research and scientific papers

Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties

The invention relates to a novel group of isonitrile compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties

The invention relates to a novel group of iminc compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties

The invention relates to a novel group of formamide compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

Imidazole compounds, use and process of making

Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

Pyridyl imidazole compounds and compositions

Novel 1, 4, 5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

1-Substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency

A series of 1-alkyl- or -aryl-4-aryl-5-pyridinylimidazoles (A) were prepared and tested for their ability to bind to a recently discovered protein kinase termed CSBP and to inhibit lipopolysaccharide (LPS)-stimulated TNF production in mice. The kinase, CS